Last Loaded on Web: Wednesday, May 01, 2013
|File Description||Print Counterparts||DIALINDEX/OneSearch Categories||Basic Index||Rank|
|Subject Coverage||Dialog File Data||Contact||Additional Indexes||Map|
|Sources||Geographic Coverage||Terms and Conditions||Limit||Predefined Format Options|
|Tips||Special Features||Sample Record||Sort||Rates|
Pharmaprojects reports on the progress of new pharmaceutical products, both new chemical entities and biotechnological entities, at all stages of development from early pharmacological studies either to final launch in all major markets or to discontinuation for scientific or commercial reasons.
File 128 is the public file; File 928 is the subscriber file, available to those who subscribe to the print Pharmaprojects.
USE FILE 128
to track pharmaceutical products in all stages of development.
USE /CO OR CO=
to find companies of interest.
USE /NA OR NA=
to search Drug names.
to search for Target Data.
Pharmaprojects primarily addresses the information needs of the pharmaceutical industry and closely related fields, but is also of interest to those involved in the evaluation of pharmaceutical company performance. Each entry contains the product name, synonyms, originating company and development status, licensees and development status, stage of development in up to 40 countries, rigorously classified therapeutic activity, drug protein target, chemical name (conforming to CAS index name format where possible), CAS® Registry Number, molecular formula, pharmacology and patent/priority data, and descriptive text with key literature references.
Pharmaprojects is compiled from both published and unpublished sources. A considerable amount of information is obtained directly from the companies involved in product development. In addition, Pharmaprojects staff attend international meetings to obtain information directly from research scientists. They also scan conference proceedings and the scientific and medical literature to track new products. Pharmaprojects also has a rigorous programme of contacting the companies in the publication and regularly scanning their websites to ensure that Pharmaprojects is a completely up-to-date source of international pharmaceutical product development information.
|Dates Covered:||Products in active development|
|File Size:||More than 35,000 records as of July 2012|
|CASREGNO||CAS(R) Registry Numbers-Chemical and Medical Files|
|DRUGDEV||Drug Development Pipeline|
|PHARMR||Pharmacology + RINGDOC-Files|
Pharmaprojects is provided by Informa UK Ltd. Questions concerning file content should be directed to:
69-77 Paul Street
London, EC2A 4LQ
For Dialog's Electronic Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply.
Information in this database is copyrighted by Informa UK Ltd. All rights reserved. Informa UK Ltd. makes no warranties, express or implied, with respect to the accuracy, quality, validity, or completeness of this database or the information therein.
Informa UK Ltd. wishes to protect against infringement of its copyright and the conditions of use of its databases while allowing fair use of material supplied to its customers. Informa UK Ltd. requires payment of a fair and reasonable fee for reproduction and redistribution of information in its database(s) EXCEPT those activities listed below and those covered by the ERA(sm) service.
ALLOWED WITHOUT PERMISSION OR CHARGE
1. Online users of Informa UK Ltd. online databases may download data from those databases onto a personal computer (PC) or into their personal electronic mailbox and integrate that information into a computer file held on that PC.
2. Members of staff of the customer organisation at the customer location where the Informa UK Ltd. data is downloaded may examine the computer file holding that data, provided that this is done at the PC on which it is held.
3. Information downloaded onto a receiving PC may be moved to another PC located at the customer location provided the Informa UK Ltd. data is held on only one (1) PC and is accessible only at that PC.
4. Permission is granted to make one (1) electronic copy of the downloaded Informa UK Ltd. data for back-up security purposes to be used only if the first copy becomes unusable.
5. Online users may make occasional printed hardcopies of the downloaded Informa UK Ltd. data and this hardcopy may be examined by members of the customer organisation working at the customer location where the downloading took place. The hardcopy may be kept for reference in a central location such as a library at the customer location where downloading took place. Additional copying of this hardcopy is a breach of the copyright of Informa UK Ltd.
6.The downloaded Informa UK ltd. data is restricted to employees of the customer and may not be exploited whether by way of sale, licence or to otherwise to any third party.
7. Informa UK Ltd. data may only be held in electronic form for a maximum period of 60 days from the date it is first downloaded and must then be deleted.
|(c)2012 Informa UK Ltd. All rights reserved.|
|/DN,DN=,/NA,NA=||Drug Name: venlafaxine hydrochloride|
|/ST,ST=||Global Status: Launched|
|/CO,CO=,/LO,LO=||Originator: Osmotica [Launched]|
|/CO,CO=,/LI,LI=||Licensee: UCB [Launched]|
|LU=||Latest Upd: Updated On Latest Change|
|20120625 Product details confirmed|
|/TC||Therapy: Description – Status|
|Antidepressant -- [Launched]|
|(. . .)|
|/RO||Rte of Admin: Description|
|Oral; Oral, swallowed|
|5 Hydroxytryptamine uptake inhibitor|
|Adrenergic transmitter uptake inhibitor|
|Serotonin and norepinephrine reuptake inhibitor|
|/IN||Indication: Description – Status|
|Depression, major depressive disorder – Launched|
|Social anxiety disorder – Launched|
|/TG||TARGET DATA: 6530: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2|
|6532: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4|
|6530: Transporter > Porters (uni-, sym- and anti-)|
|6532: Transporter > Porters (uni-, sym- and anti-)|
|NC=||New Entity: No|
|RN=||CAS Reg. No: 93413-69-5|
|/CN,CN=||Chemical Name: Cyclohexanol,|
|/ST,ST=||Country Status/Licensing Opportunity|
|USA Launched 2008/Unknown|
|Event Date Event—Details|
|20080520 First Registrations--The US; Major depressive and|
|Social anxiety disorder|
|20081009 First Launches--The US; Major depressive and Social|
|20120627 New Chemical Structure—New|
|Osmotica has developed an extended-release formulation of venlafaxine|
|hydrochloride, using its Osmodex controlled-release technology, for the|
|treatment of major depressive disorder and social anxiety disorder (. . .)|
|USA; it is approved via the 505(b)(2) pathway (NDA Approval Letter, 20 May 2008,|
|EU; an MAA was filed (Company Web Page, Osmotica, 25 Jun 2012,|
|USA; it is marketed in the US by Upstate Pharma (UCB) (Press|
|release, Osmotica, 9 Oct 2008, http://www.osmotica.com/index.php?flag=what_is_new).|
|None||--||All Basic Index Fields||Word||S ABBOTT|
|/CO||CO||Company Name1,2||Word||S OSMOTICA/CO|
S VENALFAXINE HYDROCHLORIDE/DN
|/LI||LI||Licensee and Status1||Word||S UCB/LI|
|/LO||LO||Originator and Status1||Word||S OSMOTICA/LO|
|/NA||NA||Drug Name1,3||Word||S VENAFAXINE(W)HYDROCHLORIDE/NA|
|/OM||OM||Origin of Material||Word||S CHEMICAL(w)SYNTHETIC?/OM|
S 5 HYDROXYTRYPTAMINE?/PH
|/PK||PK||Pharmacokinetic Data||Word||S HUMAN(F)CMAX/PK|
|/RO||RO||Route of Administration Text||Word||S ORAL/RO|
|/TC||TC||Therapeutic Class Text||Word
S FORMULATION MODIFIED?/TC
|/TF||TF||Target Family||Word||S ENZYME(W)KINASE/TF|
|/TG||TG||Target Data||Word||S 2322/TG|
|/UP||UP||Major Events||Word||S MAJOR(W)DEPRESSIVE/UP|
1 Searchable in the Basic Index and in the Additional Indexes.
2 Includes Originator and Licensee.
3 Includes Chemical Name, Laboratory Code, and Brand Name.
4 Includes Laboratory Code and Brand Name.
|AC=||AC||Patent Application Country||Phrase||S AC=GB|
|AD=||AD||Patent Application Date||Phrase||S AD=20110327|
|AY=||AY||Priority Application Date1,2||Phrase||S AY=2011|
|None||AZ||DIALOG Accession Number|
|CO=||CO||Company Name1,2||Phrase||S CO=OSMOTICA|
|DN=||DN||Drug Name1||Phrase||S DN=VENALFAXINE?|
|LU=||LU||Latest Update1||Phrase||S LU=20120625|
|MF=||MF||Molecular Formula||Phrase||S MF=C22H22N2O4|
|MW=||MW||Molecular Weight||Numeric||S MW=35.45|
|NA=||NA||Drug Name1,3||Phrase||S NA=VENALFAXINE HYDRO?|
|NC=||NC||New Chemical Entity||Phrase||S NC=YES|
|PC=||PC||Patent Country||Phrase||S PC=GB|
|PH=||PH||Pharmacology||Phrase||S PH=5 HYDROXYTRYPTAMINE?|
|PN=||PN||Patent Number||Phrase||S PN=EP 02731178.6|
|PY=||PY||Revision Year||Phrase||S PY=2012|
|RN=||RN||CAS(R) Registry Number||Phrase||S RN=50-28-2|
|TG=||TG||Target Data1||Phrase||S TG=2322|
|UP=||UP||Major Events||Phrase||S UP=20080520|
|/ACTIVE||Drugs in Development||S PHASE(W)III/ACTIVE|
|/CEASED||Discontinued Drugs||S ANTIASTHMA/CEASED|
|/LAUNCHED||Fully Developed Drugs||S SULINDAC/LAUNCHED|
|/YYYY||Publication Year||S TC=D5A/2012|
|CO, DN, LO, NA, PY||SORT S1/ALL/LO|
|All phrase- and numeric-indexed fields in the Additional Indexes can be ranked.||RANK CO S3|
|DN, NA, RN, SY||MAP NA TEMP S2|
MAP SYRN TEMP S1
|The full record price will be charged for any field displayed with codes. User-defined formats can be specified using the display codes indicated in the Search Options tables.||TYPE S3/CO,NA/1-5|
|1||--||DIALOG Accession Number|
|4||--||Full Record with Tagged Fields|
|6||Free||DIALOG Accession Number, Drug Name|
|8||Short||DIALOG Accession Number, Drug Name|
|K||--||KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats|
|DIALOG Accession Number||TYPE 0000032850/5
Rates For File: Pharmaprojects Cost per DialUnit: $105.00 Cost per minute: $23.83 Rank Elements $0.00 ALERT (default) $95.00 ALERT (Monthly) $162.00 ALERT (Biweekly/twice a month) * $108.00 ALERT (Weekly) $95.00 ALERT (Daily) * $55.00 ALERT (Calendar weekly) * $95.00 ALERT (Intraday) * $55.00 * = custom scheduled Alerts only ALERT Number of included prints 0 Format Types Prints 1 $0.00 $0.00 2 $60.00 $60.00 3 $60.00 $60.00 4 $60.00 $60.00 5 $60.00 $60.00 6 $0.00 $0.00 7 $60.00 $60.00 8 $0.00 $0.00 9 $60.00 $60.00 19 $60.00 $60.00 KWIC95 $60.00 NA KWIC96 $60.00 NA REDIST/COPY Multiplier Table: Range Multiplier 1-2 1.00 3-25 1.50 26-100 3.00 101-200 4.00 201-500 6.00 501-1000 8.00 1001 or more 10.00 ARCHIVE Multiplier Table: Range Multiplier 1-25 1.50 26-200 3.00 201-500 6.00 501-1000 8.00 1001 or more 10.00 --------------------------------- A charge of $20.00 applies to each CSS (Chemical Structure Search) whether searching in one database or across multiple databases. The standard output charges for each database apply to any documents retrieved.
Rates For File: Pharmaprojects - subscribers Cost per DialUnit: $105.00 Cost per minute: $23.83 ALERT (default) $55.00 ALERT (Monthly) $84.00 ALERT (Biweekly/twice a month) * $66.00 ALERT (Weekly) $55.00 ALERT (Daily) * $55.00 ALERT (Calendar weekly) * $55.00 ALERT (Intraday) * $55.00 * = custom scheduled Alerts only ALERT Number of included prints 0 Format Types Prints 1 $0.00 $0.00 2 $30.00 $30.00 3 $30.00 $30.00 4 $30.00 $30.00 5 $30.00 $30.00 6 $0.00 $0.00 7 $30.00 $30.00 8 $0.00 $0.00 9 $30.00 $30.00 19 $30.00 $30.00 KWIC95 $30.00 NA KWIC96 $30.00 NA REDIST/COPY Multiplier Table: Range Multiplier 1-2 1.00 3-25 1.50 26-100 3.00 101-200 4.00 201-500 6.00 501-1000 8.00 1001 or more 10.00 ARCHIVE Multiplier Table: Range Multiplier 1-25 1.50 26-200 3.00 201-500 6.00 501-1000 8.00 1001 or more 10.00 --------------------------------- A charge of $20.00 applies to each CSS (Chemical Structure Search) whether searching in one database or across multiple databases. The standard output charges for each database apply to any documents retrieved.